Adrian Krainer was shopping for groceries two days before Christmas in 2016 when a colleague called with terrific news.

The federal government had just approved the first drug for spinal muscular atrophy, the leading genetic cause of death in infants. Krainer, a molecular genetics professor at Cold Spring Harbor Laboratory on Long Island, N.Y., had worked on the scientific underpinnings of the medicine for more than 15 years. Now Biogen, the Cambridge biotech that shepherded it to approval, could start selling the life-saving drug, called Spinraza.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy